Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy
03:41pm, Monday, 28'th Mar 2022 Zacks Investment Research
The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a d
Are These 2 Rivals Beating Pfizer and Moderna?
10:00am, Monday, 28'th Mar 2022 The Motley Fool
They're winning when it comes to orders.
Which Company Has the Biggest COVID Program? The Answer Isn't Moderna.
12:00pm, Sunday, 27'th Mar 2022 The Motley Fool
Another player has stuffed its pipeline with many coronavirus candidates.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
09:45pm, Friday, 25'th Mar 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed at $43.28 in the latest trading session, marking a -0.05% move from the prior day.
These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022
08:00pm, Friday, 25'th Mar 2022 The Motley Fool
Looking for small healthcare companies with huge revenue opportunities? Try these.
Pfizer's (PFE) RSV Jab Gets Another Breakthrough Therapy Tag
03:03pm, Friday, 25'th Mar 2022 Zacks Investment Research
The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.
Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma
01:47pm, Friday, 25'th Mar 2022 Zacks Investment Research
Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.
Where to Invest $100 Right Now
01:00pm, Friday, 25'th Mar 2022 The Motley Fool
A little bit of money can go a long way with thorough research and smart investments.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
09:50pm, Thursday, 24'th Mar 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed the most recent trading day at $43.30, moving +0.91% from the previous trading session.
This group of stocks is flagging a rebound, and that's good news for the S&P 500, says technical analyst
01:05pm, Tuesday, 22'nd Mar 2022 MarketWatch
Where is the market going after last week's rally? Our call of the day from MKM's chief strategist is looking at healthy signals from the healthcare sector.
Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
03:29pm, Monday, 21'st Mar 2022 Benzinga
After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock.
The Moderna Analyst: BofA Securities analyst Geoff M
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
09:45pm, Friday, 18'th Mar 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed at $43.02 in the latest trading session, marking a -0.07% move from the prior day.
AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death
05:15pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
02:00pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog Highlights Pfizer,Coca-Cola, Adobe, SAP SE, and Glaxo Smith Kline
10:36am, Tuesday, 15'th Mar 2022 Zacks Investment Research
Pfizer,Coca-Cola, Adobe, SAP SE, and Glaxo Smith Kline are part of today's Analyst Blog.
